Tchaikapharma High Quality Medicines Inc. is devoted to providing individuals and families with a wide range of affordable contemporary high-quality pharmaceuticals fighting socially significant diseases.
Tchaikapharma’s latest medicinal product to receive marketing authorisation from the Bulgarian Drug Agency is Clopasa (colchicine) 0.5 mg tablets – the first gout treatment in the company’s broad portfolio. Clopasa belongs to the group of medicines with antipathic action. It is used for the treatment of acute attacks of gout, in the condition of […]
The newest medicinal product to receive Marketing Authorization from the Medicines Executive Agency is: Semefro 50 mg/850 mg film-coated tablets Semefro 50 mg/1000 mg film-coated tablets Active ingredients: sitagliptin/metformin hydrochloride Semefro contains two different medicines called sitagliptin and metformin. – Sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) […]
The turnover from transactions with Bulgarian shares reached just under BGN 6 million, and two-thirds of it (just over BGN 4 million) was formed by transactions with shares of Tchaikapharma High Quality Medicines. Another 4 companies formed another quarter of the turnover, SOFIX recorded a minimal decrease. Read the full article here in Bulgarian.
Tchaikapharma has launched two new medicinal products on the market, which are already commercially available: Methylprednisolone-Chaikapharma (methylprednisolone) 40 mg powder and solvent for for injection solution TromBai (cilostazol) 100 mg tablets The distributor of the medicinal products is Commercial League – Global Pharmа Center.
On July 7, 2022, the Bulgarian Credit Rating Agency (BCRA) has awarded the company with the highest market capitalization on the Bulgarian Stock Exchange Tchaikapharma a long-term credit rating of “BBB-” and a short-term “A” on a national scale. With this, BCRA expresses its opinion that the company maintains a very good financial position with […]